Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 648143, 15 pages
http://dx.doi.org/10.1155/2015/648143
Clinical Study

Clinical Safety and Immunogenicity of Tumor-Targeted, Plant-Made Id-KLH Conjugate Vaccines for Follicular Lymphoma

1DT/Consulting Group, 2695 13th Street, Sacramento, CA 95818, USA
2DAVA Oncology LP, Two Lincoln Center, 5420 LBJ Freeway, Suite 410, Dallas, TX 75240, USA
3Ross University School of Medicine, P.O. Box 266, Portsmouth, Dominica
4Baylor University Medical Center, C. A. Sammons Cancer Center, 3535 Worth Street, Dallas, TX 75246, USA
5University of Texas, Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA
6Clínica Universidad de Navarra, Avenida Pío XII 36, 31008 Pamplona, Spain
7CIMA, Universidad de Navarra, Avenida Pío XII 55, 31008 Pamplona, Spain
8Icon Genetics GmbH, Weinbergweg 22, 06120 Halle, Germany
9St. George’s Hospital Medical School, Cranmer Terrace, London SW17 0RE, UK
10Bayer Pharma AG, Gebäude 402, Raum 106, 42113 Wuppertal, Germany

Received 6 February 2015; Revised 11 April 2015; Accepted 12 April 2015

Academic Editor: Haiqing Ma

Copyright © 2015 Daniel Tusé et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. “ACS Cancer Facts & Figures 2011,” 2011.
  2. American Cancer Society, ACS Cancer Facts & Figures 2014, American Cancer Society, 2014.
  3. T. M. Grogan and M. A. Jaramillo, “Pathology of non-Hodgkin's lymphoma,” in Malignant Lymphoma, M. L. Grossbard, Ed., pp. 1–30, BC Decker, Madrid, Spain, 2002. View at Google Scholar
  4. M. Bendandi, “Aiming at a curative strategy for follicular lymphoma,” CA: A Cancer Journal for Clinicians, vol. 58, no. 5, pp. 305–317, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. B. S. Kahl, F. Hong, M. E. Williams et al., “Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402,” Journal of Clinical Oncology, vol. 32, no. 28, pp. 3096–3102, 2014. View at Publisher · View at Google Scholar
  6. L. W. Kwak, M. J. Campbell, D. K. Czerwinski, S. Hart, R. A. Miller, and R. Levy, “Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors,” The New England Journal of Medicine, vol. 327, no. 17, pp. 1209–1215, 1992. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Bendandi, C. D. Gocke, C. B. Kobrin et al., “Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma,” Nature Medicine, vol. 5, no. 10, pp. 1171–1177, 1999. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Inogés, M. Rodrìguez-Calvillo, N. Zabalegui et al., “Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma,” Journal of the National Cancer Institute, vol. 98, no. 18, pp. 1292–1301, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Yáñez, Y. Barrios, E. Ruiz, R. Cabrera, and F. Díaz-Espada, “Anti-idiotypic immunotherapy in follicular lymphoma patients: results of a long follow-up study,” Journal of Immunotherapy, vol. 31, no. 3, pp. 310–312, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. C. H. Redfern, T. H. Guthrie, A. Bessudo et al., “Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses,” Journal of Clinical Oncology, vol. 24, no. 19, pp. 3107–3112, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. A. A. Mccormick, M. H. Kumagai, K. Hanley et al., “Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 2, pp. 703–708, 1999. View at Publisher · View at Google Scholar · View at Scopus
  12. A. A. McCormick, S. Reddy, S. J. Reinl et al., “Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a phase I clinical study,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 29, pp. 10131–10136, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Bendandi, S. Marillonnet, R. Kandzia et al., “Rapid, high-yield production in plants of individualized idiotype vaccines for non-Hodgkin's lymphoma,” Annals of Oncology, vol. 21, no. 12, pp. 2420–2427, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Bendandi, “Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures,” Nature Reviews Cancer, vol. 9, no. 9, pp. 675–681, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. S. S. Neelapu and L. W. Kwak, “Vaccine therapy for B-cell lymphomas: next-generation strategies,” Hematology/American Society of Hematology. Education Program, pp. 243–249, 2007. View at Google Scholar · View at Scopus
  16. D. Tusé, “Safety of plant-made pharmaceuticals: product development and regulatory considerations based on case studies of two autologous human cancer vaccines,” Human Vaccines, vol. 7, no. 3, pp. 322–330, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Y. Gleba, D. Tusé, and A. Giritch, “Plant viral vectors for delivery by Agrobacterium,” Current Topics in Microbiology and Immunology, vol. 375, pp. 155–192, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Giritch, S. Marillonnet, C. Engler et al., “Rapid high-yield expression of full-size IgG antibodies in plants coinfected with noncompeting viral vectors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 40, pp. 14701–14706, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. V. Klimyuk, G. Pogue, S. Herz, J. Butler, and H. Haydon, “Production of recombinant antigens and antibodies in Nicotiana benthamiana using ‘magnifection’ technology: GMP-compliant facilities for small- and large-scale manufacturing,” Current Topics in Microbiology and Immunology, vol. 375, pp. 127–154, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. US Food and Drug Administration, United States Code of Federal Regulations, Title 21 (Food and Drugs), Part 210: Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs, vol. 4, US Food and Drug Administration, 2014.
  21. US Food and Drug Administration, United States Code of Federal Regulations, Title 21 (Food and Drugs), Part 211: Current Good Manufacturing Practice for Finished Pharmaceuticals, vol. 4, US Food and Drug Administration, 2014.
  22. S. Marillonnet, C. Thoeringer, R. Kandzia, V. Klimyuk, and Y. Gleba, “Systemic Agrobacterium tumefaciens-mediated transfection of viral replicons for efficient transient expression in plants,” Nature Biotechnology, vol. 23, no. 6, pp. 718–723, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. CBER, FDA Guidance for Industry, ‘Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials’, Center for Biologics Evaluation and Research, 2007.
  24. ICH, Guidance for Industry E6 Good Clinical Practice: Consolidated Guidance, ICH, 1996.
  25. J. W. Friedberg, P. Cohen, L. Chen et al., “Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study,” Journal of Clinical Oncology, vol. 26, no. 2, pp. 204–210, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. B. S. Kahl, N. L. Bartlett, J. P. Leonard et al., “Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study,” Cancer, vol. 116, no. 1, pp. 106–114, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Heider and N. Niederle, “Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas,” Anti-Cancer Drugs, vol. 12, no. 9, pp. 725–729, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. Leukine, “Leukine (sargramostim) monograph,” 2013.
  29. S. Inogés, A. López-Díaz de Cerio, N. Zabalegui et al., “Prolonged idiotypic vaccination against follicular lymphoma,” Leukemia and Lymphoma, vol. 50, no. 1, pp. 47–53, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. H. J. Park and S. S. Neelapu, “Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials,” British Journal of Haematology, vol. 142, no. 2, pp. 179–191, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. R. van Ree, M. Cabanes-Macheteau, J. Akkerdaas et al., “β(1,2)-xylose and α(1,3)-fucose residues have a strong contribution in IgE binding to plant glycoallergens,” The Journal of Biological Chemistry, vol. 275, no. 15, pp. 11451–11458, 2000. View at Publisher · View at Google Scholar · View at Scopus
  32. K. Foetisch, S. Westphal, I. Lauer et al., “Biological activity of IgE specific for cross-reactive carbohydrate determinants,” Journal of Allergy and Clinical Immunology, vol. 111, no. 4, pp. 889–896, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Westphal, D. Kolarich, K. Foetisch et al., “Molecular characterization and allergenic activity of Lyc e 2 (beta-fructofuranosidase), a glycosylated allergen of tomato,” European Journal of Biochemistry, vol. 270, no. 6, pp. 1327–1337, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Koprivova, C. Stemmer, F. Altmann et al., “Targeted knockouts of Physcomitrella lacking plant-specific immunogenic N-glycans,” Plant Biotechnology Journal, vol. 2, no. 6, pp. 517–523, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. M. J. van der Veen, R. van Ree, R. C. Aalberse et al., “Poor biologic activity of cross-reactive IgE directed to carbohydrate determinants of glycoproteins,” The Journal of Allergy and Clinical Immunology, vol. 100, no. 3, pp. 327–334, 1997. View at Publisher · View at Google Scholar · View at Scopus
  36. D. Tusé, T. Tu, and K. A. McDonald, “Manufacturing economics of plant-made biologics: case studies in therapeutic and industrial enzymes,” BioMed Research International, vol. 2014, Article ID 256135, 16 pages, 2014. View at Publisher · View at Google Scholar
  37. M. Zamponi, W. Weichel, F. Thieme, and J.-E. Butler-Ransohoff, “Individualized cancer vaccines: an automated system approach to sequence identification and vector cloning,” in Proceedings of the 2nd International Conference on High-Throughput Process Development, Avignon, France, 2012.